AAX BIOTECH

aaxbiotech.com

aaxbiotech.com • Likely startup • New

Likely startup • New

Actively hiring

Drug Discovery

Biotechnology

As featured in

News Powered by Cision

Menafn

30-31 BIOMARKERS - A good marker

Overview

News

Salaries

Products

People

Growth

Offices

Financials

Funding and backers

Momentum

15/100

in the news

Last sign of life

this month

a posting or a news item

Investors in similar startupsfunds that back the companies most like this one

Pear VC

backs Portal

Summit Partners

backs Integrated DNA Technologies

backs Ability Pharma

backs NaluBio

backs ONAVA

backs Ability Pharma

Similar startupsby what they do, their industry and backers

NaluBio51-200 employees

Our proprietary ECS Technology Platform uses AI and biological modeling to accelerate the development of prescription therapeutics.

Integrated DNA Technologies3 roles

Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the…

PROSION

PROSION Therapeutics is a drug development company that utilises cutting-edge technology to unlock so far undruggable targets and address…

XYLO11-50 employees

Xylo is pioneering next-generation therapeutics designed to rewire neural circuits and restore brain function. Discover our innovative…

ONAVA

Biology meets artificial and human intelligence for next-generation therapeutics. Onava is built differently. Our platform compounds in…

Prolific MachinesSeries B $55M · 2 yr ago • Founded 2020 • 51-200 employees • 4 roles

Difficult protein production made simple. A next-generation expression system for next-generation therapeutics.

Overview

0 About Us AAX Biotech AB is a research-driven biotech company with proprietary technologies that solve unmet needs in the development of next-generation antibody therapeutics. We offer a unique solution to a recognized problem in a rapidly growing market.

News

News News Powered by Cision 2 months ago

AAX Biotech Enters Next Phase of Collaboration with Daiichi Sankyo Following Initial Evaluation of Opti-mAb Technology

Swedish biotech company AAX Biotech AB today announced that its research and development

Report

News menafn 6 months ago

AAX Biotech And Evitria To Expand Access To Opti-Mab Technology In Early Antibody Development Read more

Report

News News Powered by Cision 8 months ago

AAX Biotech secures investment from Trio Impact Invest

Biotech company AAX Biotech, a leading innovator in technologies for antibody-based medicines,

Report

News PharmaTimes 9 months ago

AAX Biotech and Vascurie announce new neuro-oncology collaboration

The collaboration will help to advance a pipeline of antibody candidates

Report

News menafn 3 years ago

AAX Biotech forms strategic collaboration with Oblique Therapeutics for therapeutic antibody development

AAX Biotech forms strategic collaboration with Oblique Therapeutics for therapeutic antibody development. The collaboration will commence with AAX Biotech applying its cutting-edge Seqitope technology to characterize antibody candidates of Oblique Therape

Report